Dinutuximab beta (Qarziba)
Jump to navigation Jump to search
Mechanism of action
Diseases for which it is used
History of changes in EMA indication
- 2017-05-08: Initial authorisation as Qarziba. Qarziba is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation. In patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin 2 (IL 2).
- 2017-05-08: Initial authorisation as Qarziba. Qarziba is indicated for the treatment of patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. Qarziba should be combined with interleukin 2 (IL 2).
Also known as
- Brand name: Qarziba